4DMedical’s CT:VQ™ Faces Market Test Amid Rapid US and Brazil Expansion
4DMedical secures a major commercial breakthrough with Stanford University adopting its FDA-cleared CT, VQ™ technology, while its partnership with AstraZeneca rapidly scales lung screening across Brazil.
- Stanford University first US academic center to commercially implement CT, VQ™
- Expanded contract allows up to 20,000 CT scans annually at Stanford
- AstraZeneca lung screening program in Brazil grows to five additional hospitals
- Brazil expansion adds approximately 38,000 CT scans per year
- CT – VQ™ positioned as a new standard replacing nuclear medicine VQ scans
Stanford University Pioneers CT, VQ™ Commercial Use
Less than two months after receiving FDA clearance, 4DMedical has achieved a significant milestone with Stanford University becoming the first US Academic Medical Centre to adopt its CT, VQ™ technology commercially. This adoption marks a pivotal moment for 4DMedical, as Stanford’s 3D Quantitative Imaging Laboratory, renowned for medical imaging innovation, integrates CT, VQ™ into its clinical workflow under a pay-per-scan model. This approach not only facilitates reimbursement pathways but also accelerates real-world evidence generation, crucial for broader clinical acceptance.
The expanded agreement with Stanford builds on an existing relationship, enabling up to 20,000 CT scan analyses annually across 4DMedical’s suite of respiratory imaging solutions. The inclusion of CT, VQ™; which combines ventilation and perfusion analysis without the need for contrast agents; positions it as a transformative alternative to traditional nuclear medicine ventilation-perfusion scans, offering superior resolution and patient accessibility.
Strategic Rollout Across Leading US Academic Centers
Stanford’s commercial deployment is the first step in 4DMedical’s broader US rollout strategy targeting Key Opinion Leader sites at leading Academic Medical Centres. These centers will be instrumental in validating CT, VQ™ clinically, educating physicians, and driving adoption. By anchoring its commercialisation efforts at globally respected institutions, 4DMedical aims to establish CT, VQ™ as the new standard of care in pulmonary imaging, potentially reshaping cardiothoracic diagnostics.
Rapid Expansion of Lung Health Screening in Brazil
Meanwhile, 4DMedical’s partnership with AstraZeneca is gaining momentum in Brazil, with the Lung Health Screening Program expanding to five additional hospitals. This expansion increases the program’s annual CT scan volume by approximately 38,000, covering a mix of high-volume urban and regional centers. The new hospitals include prominent facilities in São Paulo and Joinville, enhancing the program’s scalability and data diversity.
The initiative leverages 4DMedical’s advanced imaging analytics to detect lung cancer and incidental findings such as coronary artery calcification and early-stage COPD. Combined with AstraZeneca’s commitment to respiratory health, the program aims to improve early detection and patient outcomes through actionable clinical insights.
Looking Ahead, Momentum and Market Impact
4DMedical’s CEO Andreas Fouras highlighted the rapid uptake and growing excitement around CT, VQ™, underscoring the company’s confidence in a strong fiscal year 2026. The dual developments in the US and Brazil not only validate the company’s technology and commercial strategy but also signal a fundamental shift in respiratory imaging and lung health management globally.
Bottom Line?
With Stanford’s commercial adoption and Brazil’s program expansion, 4DMedical is poised to redefine lung imaging standards worldwide.
Questions in the middle?
- How quickly will other leading US academic centers follow Stanford in adopting CT – VQ™?
- What financial impact will the expanded contracts have on 4DMedical’s revenue in FY26?
- How will clinical outcomes from the Brazil screening program influence broader global adoption?
